NCT03830710

Brief Summary

Objectives: Investigating the level of salivary 8-hydroxy-2-deoxyguanosine (8-OHdG) and total antioxidant capacity (TAC) in oral premalignant and malignant lesions in order to determine their diagnostic value for the malignant patients. Design: 120 subjects diagnosed with oral leukoplakia, oral lichen planus (OLP) and oral squamous cell carcinoma (OSCC) along with healthy control subjects were included. Salivary samples from all participants were collected. 8-OHdG was measured by ELISA technique and the TAC level was assessed by a photometric test system.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2018

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2018

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2018

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

January 28, 2019

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 5, 2019

Completed
Last Updated

February 20, 2019

Status Verified

February 1, 2019

Enrollment Period

6 months

First QC Date

January 28, 2019

Last Update Submit

February 19, 2019

Conditions

Keywords

Squamous cell carcinoma8-hydroxy-2- deoxyguanosineAntioxidant

Outcome Measures

Primary Outcomes (2)

  • Salivary 8-OHdG

    8-OHdG have a critical role in the pathogenesis of malignant lesions

    1 year

  • salivary TAC

    OSCC might be used as a tool to help diagnosis of OSCC but not to differentiate between various malignant grades

    1 year

Study Arms (4)

Group A

30 patients diagnosed with oral leukoplakia

Group B

30 patients diagnosed with oral lichen planus

Group C

30 patients having oral squamous cell carcinoma with the tongue being the most commonly affected site

Group D

30 age and gender matched individuals having no oral mucosal lesions acting as a control group

Eligibility Criteria

Age35 Years - 63 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

The included subjects were all assessed medically according to the modified Cornell Medical index (Kerr \& Millard, 1965).

You may qualify if:

  • All included individuals were not under any current medication, suffering from any systemic condition or having any other oral mucosal disorder.

You may not qualify if:

  • Pregnant or lactating females
  • subjects having systemic disorder or taking medications;
  • subjects who suffer from any other mucosal lesions.
  • severe periodontal inflammation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sandy hassan shaaban

Cairo, Egypt

Location

MeSH Terms

Conditions

Carcinoma, Squamous Cell

Condition Hierarchy (Ancestors)

CarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsNeoplasms, Squamous Cell

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer

Study Record Dates

First Submitted

January 28, 2019

First Posted

February 5, 2019

Study Start

April 1, 2018

Primary Completion

October 1, 2018

Study Completion

December 1, 2018

Last Updated

February 20, 2019

Record last verified: 2019-02

Locations